Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest update is out from Cizzle Biotechnology Holdings PLC ( (GB:CIZ) ).
Cizzle Biotechnology Holdings PLC has announced significant commercial progress in the USA, as its North American licensing partner, Cizzle Bio Inc, has entered into an agreement with a large clinical diagnostics laboratory group to launch the CIZ1B biomarker test across the country. This move is expected to enhance the company’s market presence and operational scale in North America, aiming to improve early-stage lung cancer detection. Additionally, Cizzle and BIO have agreed to a revised royalty payment schedule, ensuring the remaining advance royalties are paid by the end of 2026, ahead of the original timeline. This development reflects BIO’s commitment to expanding the test’s reach and Cizzle’s strategic financial planning, potentially benefiting stakeholders through accelerated revenue realization.
More about Cizzle Biotechnology Holdings PLC
Cizzle Biotechnology Holdings PLC is a UK-based diagnostics developer focused on creating early cancer detection tests. The company has developed the CIZ1B biomarker into a non-invasive, cost-effective blood test for early detection of lung cancer. Cizzle has entered into commercial royalty-bearing arrangements to license its proprietary technology and collaborates with centers of excellence in cancer care. The company was listed on the London Stock Exchange in May 2021.
Average Trading Volume: 1,399,655
Technical Sentiment Signal: Sell
Current Market Cap: £5.15M
See more data about CIZ stock on TipRanks’ Stock Analysis page.